Triple Negative Breast Cancer: A Brief Review of its Characteristics and Treatment Options

Abstract

Triple negative breast cancer (TNBC), an aggressive variant of breast cancer, is characterized by lack of expression of the estrogen (ER) and progesterone receptors (PRs) and the human epidermal growth factor receptor (HER-2) that are commonly observed in other breast cancer subtypes. The TNBC subtype primarily occurs in younger women of African American or Hispanic descent and tumors tend to be high grade and initially responsive to chemotherapy. However, TNBC is characteristically aggressive with high recurrence, metastatic, and mortality rates. Treatment options are limited since the hormonal receptor and HER-2 antagonists typically used for other breast cancers are ineffective. As such, the mainstay of treatment of TNBC is traditional systemic cytotoxic chemotherapy. Potential future therapies for TNBC include targeted molecular strategies including poly (adenosine diphosphate ribose) polymerase (PARP) and epidermal growth factor receptor (EGFR) inhibitors and antiangiogenic agents. Further research aimed at identifying unique genetic characteristics of TNBC may allow development of other targeted molecular chemotherapy treatment options.

Keywords

triple negative breast cancer

Get full access to this article

View all access options for this article.

References

American Cancer Society, Inc. Surveillance and Health Policy Research 2010. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-026210.pdf. Accessed May 1, 2011.

American Cancer Society: Cancer Facts & Figures 2010. Atlanta, GA: American Cancer Society; 2010.

http://www.cancer.org/Cancer/BreastCancer/DetailedGuide/breast-cancer-what-is-breast-cancer. Accessed May 25, 2011.

Prat

Parker

Karginova

. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010;12(5):R68.

Kandel

Stadler

Masciari

. Prevalence of BRCA1 mutations in triple negative breast cancer (BC). J Clin Oncol. 2006;24(18S):508.

Gonzalez-Angulo

Chen

Timms

. Incidence and outcome of BRCA mutation carriers with triple receptor-negative breast cancer (TNBC). J Clin Oncol. 2010. General Session IX: Triple-negative Breast Cancer: Clinical Science Symposium. Abstract No: 160.

Hudis

Gianni

. Triple-negative breast cancer: an unmet medical need. Oncologist. 2011;16 ( Suppl 1 ):1–11.

Carey

Perou

Livasy

. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492–2502.

Millikan

Newman

Tse

. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2008;109(1):123–139.

10.

National Comprehensive Cancer Network (NCCN). The NCCN Guidelines Version 2.2011. www.nccn.org. Accessed June 5, 2011.

11.

Bauer

Brown

Cress

. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer registry. Cancer. 2007;109(9):1721–1728.

12.

Leidke

Mazouni

Hess

. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275–1281.

13.

Lin

Claus

Sohl

. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer. Cancer. 2008;113(10):2638–2645.

14.

Foulkes

Smith

Reis-Filho

. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938–1948.

15.

Isakoff

. Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J. 2010;16(1):53–61.

16.

Silver

Richardson

Eklund

. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol. 2010;28(7):1145–1153.

17.

Goldhirsch

Ingle

Gelber

. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009;20(8):1319–1329.

18.

Staudacher

Cottu

Dieras

. Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience. Ann Oncol. 2011;22(4):848–856.

19.

O’Shaughnessy

Osborne

Pippen

. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med. 2011;364 (3):205–214.

20.

Carey

Rugo

Marcom

. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. J Clin Oncol. 2008;26:43s. (Abstract 1009).

21.

O’Shaughnessy

Osborne

Pippen

. Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. Breast Cancer Res Treat. 2007;106:s32. (Abstract 308).

22.

Gholam

Chebib

Hauteville

. Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor-positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2 negative (triple-negative) breast cancer. Anticancer Drugs. 2007;18(7):835–837.

23.

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2010/ucm237172.htm. Accessed June 5, 2011.

24.

Carlson

RH.

Bevacizumab: Public opinion might trump science. Lan Oncol. 2011;12: 730.